After Y90-RE therapy, patients in the favorable response cohort demonstrated a lower incidence of ascites (11% vs. 33%; p = 0.001), lower levels of AFP tumor marker (77 ± 286 ng/mL vs. 452 ± 656 ng/mL; p = 0.002), lower levels of alkaline phosphatase (127 ± 55 U/L vs. 169 ± 130 U/L; p = 0.04), and higher levels of albumin (3.6 ± 0.5 g/dL vs. 3.1 ± 0.7; p ≤ 0.0001). The gene discussed is ALB; the disease is Ascites.